Compound for treating angiogenesis

Details Compound for treating angiogenesis Compound for treating angiogenesis

2007-06-05

2007-06-05

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S360100

Reexamination Certificate

active

10883482

ABSTRACT:
The present invention provides methods and pharmaceutical compositions for inhibiting expressions of HIF and HIF regulated genes, inhibiting angiogenesis, inducing cell cycle arrest in tumor cells, and treating cell proliferating diseases or conditions.

REFERENCES:
patent: 5574168 (1996-11-01), Kuo et al.
patent: 6162819 (2000-12-01), Schindler et al.
patent: 6180656 (2001-01-01), Robyr et al.
patent: 6387940 (2002-05-01), Straub et al.
patent: 6387942 (2002-05-01), Teng et al.
patent: 6410740 (2002-06-01), Robyr et al.
patent: 6518294 (2003-02-01), Teng et al.
patent: 6589997 (2003-07-01), Pillarisetti et al.
patent: 6610726 (2003-08-01), Pillarisetti et al.
patent: 6897232 (2005-05-01), Schindler et al.
patent: 2003/0072748 (2003-04-01), Black et al.
patent: 2003/0105336 (2003-06-01), Schindler et al.
patent: 2003/0186996 (2003-10-01), Teng et al.
patent: 2004/0077702 (2004-04-01), Fu et al.
patent: 0254241 (1988-01-01), None
patent: 0667345 (1995-02-01), None
patent: 1166785 (2001-06-01), None
patent: 10-2001-0060054 (2001-09-01), None
patent: WO03/024397 (2003-03-01), None
patent: WO03/082274 (2003-10-01), None
patent: WO 2004/091648 (2004-10-01), None
patent: WO 2005/030121 (2005-04-01), None
Chun, et al (Biochemical Pharmacology, 61 (Apr. 2001), 947-954), especially p. 947, compound YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole.
Ko et al., “YC-1 a Novel Activator of Platelet Guanylate Cyclase”,Blood, vol. 84, No. 12, Dec. 15, 1994, pp. 4226-4233.
Yeo et al., “YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1”,Journal of the National Cancer Institute, vol. 95, No. 7, Apr. 2, 2003, pp. 516-525.
Höckel and Vaupel, “Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects”,Journal of National Cancer Institute, vol. 93, No. 4, Feb. 21, 2001, pp. 266-276.
Dachs and Tozer, “Hypoxia Modulated Gene Expression: Angiogenesis, Metastasis, and Therapeutic Expoloitation”,European Journal of Cancer, 36, May 2000, pp. 1649-1660.
J. Martin Brown, “The Hypoxic Cell: A Target for Selective Cancer Therapy”, Eighteenth Bruce F. Cain Memorial Award Lecture,Cancer Research, 59, Dec. 1, 1999, pp. 5863-5870.
Forsythe et al., “Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1”,Molecular and Cellular Biology, Sep. 1996, pp. 4604-4613.
Wang and Semenza, “Purification and Characterization of Hypoxia-Inducible Factor 1”,The Journal of Biological Chemistry, vol. 270, No. 3, Jan. 20, 1995, pp. 1230-1237.
Maxwell et al., “The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis,”Nature, vol. 399, May 20, 1999, pp. 2710-2715.
Ivan et al., “HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2Sensing”,Science, vol. 292, Apr. 20, 2001, pp. 464-451.
Masson et al., “Independent Function of Two Destruction Domains In Hypoxia-Inducible Factor-α Chains Activated by Polyl Hydroxylation,”European Molecular Biology Organization, The EMBO Journal, vol. 20, No. 18, (2001) pp. 5197-5206.
Huang et al., “Regulation of Hypoxia-Inducible Factor 1α is Mediated by an O2-Dependent Degradation Domain Via the Ubiquitin-Proteasome Pathway,”Proc. Natl. Acad. Sci USA, vol. 95, pp. 7987-7992, Jul. 1998.
Gregg L. Semenza, “HIF-1 and Tumor Progression: Pathophysiology and Therapeutics,”Trends in Molecular Medicine, vol. 8, No. 4, Suppl. (2002), pp. S62-S67.
Zhong et al., “Overexpression of Hypoxia-Inducible Factor 1α in Common Human Cancers and Their Metastases”,Cancer Research, vol. 59, pp. 5830-5835, Nov. 15, 1999.
Birner et al., “Overexpression of Hypoxia-Inducible Factor 1α Is a Marker For an Unfavorable Prognosis in Early-Stage Invasive Cervical Cancer”,Cancer Research, vol. 60, pp. 4693-4696, Sep. 1, 2000.
Maxwell et al., “Hypoxia-Inducible Factor-1 Modulated Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth”,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 8104-8109, Jul. 1997 Medical Sciences.
Teng et al., “YC-1 A Ntric Oxide-Independent Activator of Soluble Guanylate Cyclase, Inhibits Platelet-Rich Thrombosis in Mice”,European Journal of Pharmacology, vol. 320, pp. 161-166, (1997).
Galle et al., “Effects of the Soluble Guanylyl Cyclase Activator, YC-1, on Vascular Tone, Cylcic GMP Levels and Phosphodiesterase Activity”,British Journal of Pharmacology, vol. 127, pp. 195-203 (1999).
Chun et al., “Inhibitory Effect of YC-1 on the Hypoxic Induction of Erythropoietin and Vascular Endothelial Growth Factor in Hep3B Cells”,Biochemical Pharmacology, vol. 61, pp. 947-954 (2001).
Yoshina et al., Yakugaku Zasshi, vol. 98(2), pp. 204-209, (1978).
Yoshina et al., Yakugaku Zasshi, vol. 97(9), pp. 955-961, (1977).
Jaakkola et al., “Targeting of HIF-α to the von Hippel—Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation”, Science, vol. 292, pp. 468-472, Apr. 20, 2001.
Giaccia et al., “HIF-1 As A Target For Drug Development”,Nature Reviews/Drug Discovery, vol. 2, pp. 1-9, Oct. 2003.
Semenza, “Targeting HIF-1 For Cancer Therapy”,Nature Reviews/Cancer, vol. 3, pp. 721-732, Oct. 2003.

Affiliated with

Also associated with

Rating

Compound for treating angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compound for treating angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound for treating angiogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854140